Organ-on-a-chip (OOC) technology aims to more accurately reproduce human physiology in vitro, addressing the limitations of current approaches. This field is advancing rapidly. Image Credit: CN Bio ...
Bayland Capital and founding shareholder, CN Innovations Holdings Ltd, to invest $10M and $5.5M, respectively Investment will expand product development and scaling of the organization to meet ...
The current drug discovery process is inefficient, with a significant number of drugs halting clinical trials, pending more investigational work to understand causality, or failing due to unforeseen ...
For those considering adding Organ-on-a-chip (OOC) technology into the workflow, it may be unclear where to start. Firstly, using a commercially available solution, such as CN Bio's PhysioMimix ®, ...
Recently the FDA scolded Americans interested in Ivermectin as a COVID-19 treatment by tweeting “You are not a horse. You are not a cow.” The FDA’s tendentious sarcasm is ironic given that the FDA ...
BOSTON and SEOUL, South Korea, Jan. 5, 2026 /PRNewswire/ -- Xellar Biosystems ("Xellar"), a globally leading innovator in next-generation artificial intelligence- and computer vision–assisted, ...
CN Bio, a leading developer of single and multi-organ microphysiological systems (MPS), otherwise known as organ-on-a-chip (OOC), today announced the commercial launch of its new PhysioMimix™ OOC ...
CN Bio, announced the establishment of a strategic partnership with Pharmaron. Under the agreement, Pharmaron will validate CN Bio’s PhysioMimix ® technology across existing applications and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results